Why the study?
Pseudomyogenic hemangioendothelioma can be challenging to differentiate from clinicopathologically similar conditions, which is important given its typically more indolent course.
Key points are not available for this paper at this time.
Design
Case_report
Distinguishing PHE from mimics may avoid overtreatment given its indolent course; leaves open standardized diagnostic criteria for rare vascular tumors.
Pseudomyogenic hemangioendothelioma (PHE) is a rare intermediate-grade (rarely metastasizing) vascular neoplasm that commonly presents as distinct, solitary nodules on distal extremities. It can be challenging to differentiate from clinicopathologically similar conditions. This distinction is important as PHE usually has a more indolent course.1 Until its official inclusion in the World Health Organization’s Classification of Soft Tissue and Bone Tumors in 2013, various descriptions of PHE existed in the literature.
No takes yet. Share an insight, caveat, or question.
Islam et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: